These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10875002)

  • 1. Nonclinical safety evaluation of biotechnologically derived pharmaceuticals.
    Dempster AM
    Biotechnol Annu Rev; 2000; 5():221-58. PubMed ID: 10875002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
    Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
    PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges.
    Brennan FR; Shaw L; Wing MG; Robinson C
    Mol Biotechnol; 2004 May; 27(1):59-74. PubMed ID: 15122047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Points to consider" regarding safety assessment of biotechnology-derived pharmaceuticals in non-clinical studies (English translation).
    Nakazawa T; Kai S; Kawai M; Maki E; Sagami F; Onodera H; Kitajima S; Inoue T
    J Toxicol Sci; 2004 Dec; 29(5):497-504. PubMed ID: 15729005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals.
    Snodin DJ; Ryle PR
    BioDrugs; 2006; 20(1):25-52. PubMed ID: 16573349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. History of chronic toxicity and animal carcinogenicity studies for pharmaceuticals.
    Jacobs AC; Hatfield KP
    Vet Pathol; 2013 Mar; 50(2):324-33. PubMed ID: 22700852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety assessment of pharmaceuticals: examples of inadequate assessments and a mechanistic approach to assuring adequate assessment.
    Williams GM
    Toxicol Pathol; 1997; 25(1):32-8. PubMed ID: 9061849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-clinical Safety Evaluation of Biotherapeutics - Challenges, Opportunities and new Insights.
    Blaich G; Baumann A; Kronenberg S; de Haan L; Ulrich P; Richter WF; Tibbitts J; Chivers S; Tarcsa E; Caldwell R; Crameri F
    Regul Toxicol Pharmacol; 2016 Oct; 80S():S1-S14. PubMed ID: 27578450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimum safety requirements for preclinical testing.
    Dorner F; Barrett PN; Schwartz HP; Eibl H
    Dev Biol Stand; 1993; 81():245-52. PubMed ID: 8174809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the toxicologic pathologist in the preclinical safety evaluation of biotechnology-derived pharmaceuticals.
    Pilling AM
    Toxicol Pathol; 1999; 27(6):678-88. PubMed ID: 10588549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper.
    Tomohiro M; Okabe T; Kimura Y; Kinoshita K; Maeda M; Mitobe Y; Motoyama K; Yonezawa R; Sasaki S; Fujiwara M; Watanabe K
    Toxicol Pathol; 2019 Feb; 47(2):108-120. PubMed ID: 30636562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic aspects of biotechnology products.
    Tang L; Persky AM; Hochhaus G; Meibohm B
    J Pharm Sci; 2004 Sep; 93(9):2184-204. PubMed ID: 15295780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs.
    Colbert A; Umble-Romero A; Prokop S; Chow VF; Wong T; DeSimone D; Zhou L; Pederson S
    MAbs; 2014; 6(5):1178-89. PubMed ID: 25517303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study designs for the nonclinical safety testing of new vaccine products.
    Forster R
    J Pharmacol Toxicol Methods; 2012 Jul; 66(1):1-7. PubMed ID: 22561062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.